Norges Bank
DOVA

Norges Bank’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Norges Bank’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,500
Closed -$425K – 2150
2017
Q3 		$425K Hold
17,500
– – ﹤0.01% 2102
2017
Q2 		$390K Buy
+17,500
New +$368K ﹤0.01% 2094

Other funds holding DOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Norges Bank's DOVA Position: Q4 2017 in Review

Norges Bank sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2017, closing a stake of 17,500 shares — an estimated $425K sold.

Norges Bank first reported a position in DOVA in Q2 2017 and held it in 2 quarters. The position peaked at $425K in Q3 2017. 48 funds tracked by Wall St. Rank hold DOVA as of Q4 2017.

  • Norges Bank reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Norges Bank sold 17,500 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2017, an estimated $425K.
  • Norges Bank first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • Norges Bank's Dova Pharmaceuticals, Inc. Common Stock position peaked at $425K in Q3 2017.
  • 48 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2017.

Based on Norges Bank's 13F filing for Q4 2017, filed 9 Feb 2018.